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Abstract
The single amino acid replacement Asp116His distinguishes the two subtypes HLA-B*2705 and HLA-B*2709 which are,
respectively, associated and non-associated with Ankylosing Spondylitis, an autoimmune chronic inflammatory disease. The
reason for this differential association is so far poorly understood and might be related to subtype-specific HLA:peptide
conformations as well as to subtype/peptide-dependent dynamical properties on the nanoscale. Here, we combine
functional experiments with extensive molecular dynamics simulations to investigate the molecular dynamics and function
of the conserved Arg62 of the a1-helix for both B27 subtypes in complex with the self-peptides pVIPR (RRKWRRWHL) and
TIS (RRLPIFSRL), and the viral peptides pLMP2 (RRRWRRLTV) and NPflu (SRYWAIRTR). Simulations of HLA:peptide systems
suggest that peptide-stabilizing interactions of the Arg62 residue observed in crystal structures are metastable for both B27
subtypes under physiological conditions, rendering this arginine solvent-exposed and, probably, a key residue for TCR
interaction more than peptide-binding. This view is supported by functional experiments with conservative (R62K) and non-
conservative (R62A) B*2705 and B*2709 mutants that showed an overall reduction in their capability to present peptides to
CD8+ T cells. Moreover, major subtype-dependent differences in the peptide recognition suggest distinct TCR binding
modes for the B*2705 versus the B*2709 subtype.
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Introduction
Major histocompatibility complex (MHC) class I molecules are
highly polymorphic glycoproteins involved in the presentation
of foreign peptides to cytotoxic CD8+ T lymphocytes. In this
process, which is pivotal for immune surveillance of intracellular
pathogens, a key step is the recognition of the MHC class I
complex (heavy chain (HC), b2-microglobulin (b2m) and peptide,
see Fig. 1A) by a T-cell receptor (TCR). Peptides, typically 8–10
amino acid residues long, are produced during intracellular
protein degradation [1]. A detailed knowledge of the rules
governing peptide binding arose from crystallographic studies
and peptide elution analysis from purified MHC molecules [2–7].
Less is known about the dynamic properties of the MHC class I
complex [8] and whether or how the peptide or the heavy chain
binding groove may adapt their conformation in the process of
recognition by TCR, either by induced fit or by conformational
selection [9–12].
HLA-B27 is one of the most investigated human MHC class I
antigens given the strong association with Ankylosing Spondylitis
(AS), a rheumatic autoimmune disorder [13,14]. Nevertheless,
HLA-B27 confers to carriers some immunological benefits such as
effective cytotoxic T cell (CTL) responses by presenting epitopes
from many infectious agents such as influenza virus (flu), Epstein-
Barr virus (EBV), hepatitis C virus (HCV) and human immuno-
deficiency virus (HIV) [15–18].
The pathogenic role of HLA-B27 has not yet been fully
elucidated. Notably, some HLA-B27 subtypes are not associated
with AS [19–21]. This applies to the HLA-B*2709 allele which
occurs in up to 19% of B27 healthy carriers in Sardinia [22].
B*2709 represents a good investigative tool in pairwise compar-
ative studies with B*2705, the most common B27 allele and
strongly associated with AS in worldwide populations. Indeed, the
two allelic products are distinguished only by a single substitution
in the residue 116 (Asp in B*2705 and His in B*2709) located in
the floor of pocket F where the peptide C-terminus accommodates
[23]. Asp116His is a relevant polymorphism that gives rise to
different repertoires of bound peptides and cytotoxic CD8+ T cells
(CTL) [24–26]. As an example, pVIPR, a self-peptide derived
from type I receptor of Vasoactive Intestinal Peptide evokes
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with AS, but not in B*2709 healthy individuals [26,27]. This
peptide exhibits a double conformation, canonical (pVIPR A) and
non-canonical (pVIPR B) on B*2705, and only the canonical
(pVIPR A) binding mode in complex with B*2709 [28]. This
finding allows speculating on a cause-effect correlation between
the double conformation of pVIPR and a defective negative
thymic selection that prevents autoreactive CTLs to be deleted
thus allowing them to gain access to the circulating T cell pool.
pVIPR shares high sequence similarity with pLMP2, a viral
peptide from EBV which is displayed in two drastically different
conformations by B*2705 (non-canonical) and B*2709 molecules
(canonical) [29]. The remarkable structural similarities between
pLMP2 and pVIPR on B*2705 molecules are functionally
mirrored by the occurrence of pLMP2/pVIPR cross-reactive
CTL in B*2705 positive patients with AS [29]. Both these peptides
have an Arg at position 1, a feature shared by a large portion of
B27 bound peptides [30]. Crystallographic analysis revealed tight
interactions of this residue bound in the A pocket to the three
residues Glu163 (a2-helix), Trp167 (a2-helix), and Arg62 (a1-
helix). Both van der Waals interactions as well as water-mediated
salt bridges between these residues contribute significantly to the
peptide binding [28,29,31,32].
Until now, no crystal structure of TCRs bound to B27:peptide
complexes has been solved. Therefore, no information on
conformational changes in these structures upon TCR engage-
ment is available. However, several crystal structures of other
MHC complexes bound to TCRs and sharing common key
residues (Arg62, Gln65, Ala150) with the two B27 subtypes
investigated here are available in the Protein Data Bank [33–35].
Notably, in all these structures and independently from the initial
state, the Arg62 side chain adopts a conformation enabling the
contact with the CDRa1 once the TCR engages the MHC:pep-
tide (Fig. 1B). In the pLMP2:, pVIPR: and TIS:B*2705/09 crystal
structures, the Arg62 side chain is always oriented towards the
HLA binding groove and even engaged in a (water-mediated) salt
bridge to Glu163 of the opposed a2-helix [28,29,32]. The salt
bridge is formed across the N-terminal part of the peptide. In this
conformation, the Arg62 side chain is hardly accessible for
interactions to a TCR (see Fig. 1A).
The time evolution of conformations sampled by a biomolecular
system (here MHC:peptide complexes) can be monitored at
atomic resolution by performing molecular dynamics (MD)
simulations [36]. MD simulations were already applied to the
study of various HLA-B molecules in complex with different
peptides [8,37–43].
In the present study, MD simulations of B*2705 and B*2709
molecules bound to peptides having an Arg (pVIPR, pLMP2 and
TIS) [44] or a Ser (NPflu) [45] at position 1, document a TCR-
independent but peptide-dependent conformational change of
Arg62. The simulations show a predominant solvent-exposed
conformation of the Arg62 side chain for B27:peptide complexes
with an arginine in position 1 of the peptide.
The relevance of Arg62 for T-cell recognition was investigated
by functional experiments in which self (pVIPR) or viral peptides
(pLMP2, NPflu) are presented to specific CTLs in association with
B*2705 or B*2709 mutants in which a Lys or an Ala replaces
Arg62.
Results
MD simulations of HLA-B27:peptide systems
Crystal structures of B*2705 and B*2709 with bound peptides
were resolved at 100 K [28,29,32]. Here, we investigated the
conformational dynamics focusing on the Arg62 residue of seven
different HLA:peptide systems at physiological temperature, by
MD simulations of 400 ns length. The simulated systems were
pLMP2, pVIPR, TIS associated with either B*2705 or B*2709
molecules, and NPflu in complex with B*2705 only (see Methods).
TIS is part of TIS11B, a member of epidermal growth factor early
response genes that has been eluted from both B*2705 and 09
molecules [24,46,47]. Thermodynamic and structural studies have
demonstrated an almost total equivalence of B*2705:TIS and
B*2709:TIS complexes [32,44] and therefore this peptide has been
included in the MD simulations as reference. NPflu is an
immunodominant, HLA-B27-restricted epitope derived from the
nucleoprotein of Influenza A virus and the only investigated
peptide here lacking Arg at P1 [45]. No simulation of
B*2709:NPflu was undertaken given the instability of this complex
Figure 1. MHC:peptide complex unbound (A) and bound (B) to a TCR. A) Cartoon representation of HLA*B2705 presenting the pLMP2
peptide (PDB ID: 1UXS). The peptide-binding groove is shown in beige, the a3 domain in red, the b2-microglobulin in green and the bound LMP2
peptide in blue. Arg62 and Glu163 are emphasized in stick representation. B) Cartoon representation of the binding groove of HLA-B*0801 (in beige)
in complex with an EBV derived nonapeptide (in purple) bound to the Va and Vb chains of the LC13 T-Cell receptor (in green, PDB ID: 1MI5). Arg62 of
the MHC binding groove as well as the residues of the Va chain making contacts with Arg62 (Thr26, Ser28 and Gly96) are shown in stick
representation.
doi:10.1371/journal.pone.0032865.g001
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disfavoured in the F pocket of B*2709 (His 116) [24,47].
Arg62 conformational flexibility in B*2705 and B*2709
subtypes is peptide-dependent
In pLMP2 and pVIPR pArg1 forms a direct salt bridge with
Glu163 in both B*2705 and B*2709 subtypes as shown by the x-
ray crystal structures (left panels in Fig. 2A). As a measure of the
Arg62 conformations sampled in the simulations, the minimum
distance between Arg62 and Glu163 (see Fig. 1A) was calculated
as a function of the simulation time for all systems. The
distribution of distances was used to analyze the free energy
profile along this degree of freedom, (DG(dist)) [48]:
DG dist ðÞ ~{RT ln r dist ðÞ =rmax ðÞ
r(dist) is the density of states at a given distance and rmax the
maximal density of the respective distribution [48]. The DG
profile as well as the time traces for the distance between Arg62
and Glu163 are shown in Figure 2B and C. The grey area
indicates the distance range as observed in the crystal.
The side chain of Arg62 showed a large conformational
flexibility for all systems involving peptides with a N-terminal
Arg. In these systems, the water-mediated salt bridge between
Arg62 and Glu163 present in the crystal structures was
destabilized resulting in a global rearrangement of the A pocket.
As shown in Figure 2A, the side chain of Arg62 adopted a
completely solvent exposed conformation. This exposed confor-
mation resembles the one observed for the same side chain in the
different reported MHC/TCR crystal structures (see Fig.1B) [34].
A local energy minimum corresponding to the bound conforma-
tion observed in crystal structures was found for both B*2705 and
B*2709 subtypes presenting peptides with Arg in position 1
(pVIPR, pLMP2, TIS). In these systems, the free energy profile
additionally shows the presence of stable exposed conformations of
the Arg62 side chain (local/global energy minimum corresponding
to Arg62-Glu163 distances .6.0 A ˚). For B*2705 in complex with
pLMP2, distances between Arg62 and Glu163 of 15 A ˚ and more
were observed (Fig. 2B). This separation is due to a partial
unfolding of the a1-helix resulting in an increased separation
between the two helices [43]. The contact between Arg62 and
Glu163 present in the starting structure and lost during the MD
simulation is intermediately restored for HLA-B*2705 in complex
with pVIPR in both A and B conformations (Fig. 2A top panel and
2C).
The breakage of the water-mediated salt-bridge between Arg62
and Glu163 is facilitated by the positive charges of the
guanidinium group of pArg1 and of pArg3/pLys3. These can
partially stabilize the negative charge of Glu163 after loss of
contact with Arg62 by formation of transient, partially water-
mediated, salt bridges to Glu163 (see Fig. 2D for distances between
pArg3/pLys3 to Glu163). Additionally, the Glu163-Arg62 inter-
action may be replaced by a salt bridge to the positively charged
N-terminal amine group instead of the guanidinium group of
pArg1. This occurs in the B*2705:pLMP2, B*2709:pLMP2 and
B*2709:pVIPR complexes.
Figure 2. Conformational variability of the Arg62 side chain. A) Representation of the N-terminal binding pockets of HLA-B*2705 presenting
pVIPR in non-canonical conformation (top row), of HLA-B*2709 presenting pLMP2 (2nd row) and TIS (3rd row), and of HLA-B*2705 presenting the
NPflu peptide (bottom row). Residues of the binding groove (Arg62, Glu163 and Trp167, red sticks) and the first two N-terminal residues (pArg1 and
pArg2) of the peptide (in blue) are highlighted. The x-ray structures of the respective systems are shown in the first column. For comparison, three
representative snapshots taken at different times of the simulations are depicted. Water molecules involved in water mediated salt-bridge between
Arg62 and Glu163 are shown if present (blue sphere). B) Free energy profiles as a function of the distance between Arg62 and Glu163 computed for
all eight simulated systems. The gray area indicates the range of the distances found in the corresponding crystal structures. C) Time traces of the
distance between Arg62 and Glu163 as obtained from the MD simulations (legends as in B). D) Time traces of the distance between Glu163 and
pArg3 of pLMP2 and pLys3 of pVIPR, respectively.
doi:10.1371/journal.pone.0032865.g002
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peptide lacking pArg1 but having pSer1, an uncharged, albeit
polar residue as well as pTyr3, showed a considerably different
energetic profile when compared with the other systems. A
significantly more stable salt bridge (not water-mediated) between
Arg62 and Glu163 was observed in the simulations. Such an
interaction is absent in the crystal structure of NPflu [45].
R62K and R62A replacements in B*2705 and B*2709
subtypes do not alter the cell surface expression and
molecular stability
In order to investigate the functional role of Arg62, we
performed single amino acid substitutions in both B27 subtypes.
In particular, we generated B*2705 and B*2709 mutants
substituting Arg62 by Lys (R62K) that conserves the positive
charge and by Ala (R62A) in which a non-polar residue replaces
the positively charged residue. For functional experiments, we
stably transfected the cDNAs encoding the four B27 mutants in
HeLa cells. Afterwards, HeLa transfectants have been cloned and
several different clones analysed by flow cytometry to assess the
expression of B27 mutants on the cell surface. One clone for each
B27 mutant was chosen for further experiments. The B27 mutants
expression profile has been analysed with either ME1, a mAb
recognizing the properly folded B27 molecules (heavy chain/
b2m/peptide) or HC10 that reacts with the heavy chains
dissociated from the b2m [49,50]. The staining with the
conformational dependent antibody ME1 showed an expression
level of the folded R62K and R62A B27 mutants slightly lower
and higher, respectively, than wt (Fig. 3A and C). On the opposite,
Figure 3. Cell surface expression of R62A and R62K B*2705/09 mutants on Hela transfectants. A) Surface expression of R62A and R62K
mutants within B*2705 (left panel) and B*2709 context (right panel) compared to that of wt molecules. Cells were stained with ME1 mAb and
analysed by flow cytometry analysis. B) Surface expression of free heavy chains of R62A and R62K B*2705 mutants (left panel) and R62A and R62K
B*2709 mutants (left panel) versus wt molecules analysed with HC10 mAb. Grey histograms represent wt HeLa cells (neg) used as controls. Mouse IgG
negative controls have not been shown. One representative experiment is shown here. C) Comparison of the surface expression of wt (B*2705 on left
panel; B*2709 on right panel) molecules with the relative mutants as folded heterodimers (white bars) and b2m-free heavy chains (black bars).
Untransfected HeLa cells (HeLa in the figure) do not expressed unfolded heavy chains. The results are expressed as mean fluorescence 6 SD of five/
six independent experiments.
doi:10.1371/journal.pone.0032865.g003
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R62A mutants in the context of B*2709 and, even more, in that of
B*2705 displayed an evident decreased amount of b2m-free heavy
chains compared to wt molecules (Fig. 3B and C). The data
suggest that these mutations do not induce dissociation of the three
party complexes on the cell surface. No free heavy chains are
detectable on the cell surface of untransfected HeLa cells (Fig. 3B).
Arg 62 is relevant for TCR recognition of peptides with
pArg1 associated with B*2705 and B*2709 molecules
HeLa transfectants expressing the B*2705 and B*2709 mutant
forms have been used as target cells for specific HLA-B27-
restricted CD8+ cytotoxic T cells to assess whether the substitution
of Arg62 by a conservative (Lys) or non-conservative (Ala) amino
acid could affect the T cell recognition of pVIPR and pLMP2.
The results shown in Figure 4 attest a distinct behaviour among
three different pVIPR-specific CTL lines derived from two B*2705
positive patients with AS (EP and BAR). In the case of EP1 CTL
line, the pVIPR:B*2705 mutant complexes were recognized even
better as compared to the wt molecules. On the contrary, the same
CTL line was less effective when the peptide was presented by
either R62K or R62A B*2709 mutants compared to the wt
molecules. As for EP4 from the same patient with AS, the TCR
recognition appeared highly dependent on the presence of Arg62
since the recognition of pVIPR was totally abrogated on both
R62K and R62A B*2705 mutants and on R62A B*2709 mutant
and heavily reduced (up to 70% on R62K B*2709 mutant (Fig. 4).
The effector functions of BAR28 CTL line were tested only in
the B*2705 context. It exhibited a clear lack of peptide recognition
on the non-conservative mutant R62A, and a partial decrement on
the R62K mutant compared to the wt (Fig. 4).
As for the recognition of pLMP2, we tested four CTL lines: two
from a B*2705 patient with AS (PIC) and two from two different
B*2709 individuals (DE and PMC). PIC3 and PIC5 CTL lines
behaved similarly showing reduced lytic activity against both
B*2705 and B*2709 mutant HeLa cells incubated with pLMP2 in
comparison with the wt molecules (Fig. 5). Interestingly, pLMP2
was recognized slightly better when presented by the conservative
mutant in B*2705 context vs the non-conservative one, while the
opposite occurred in the B*2709 context. DE5 displayed only a
negligible recognition of pLMP2 on mutant R62K B*2705 and the
same trend of PIC3 and PIC5 with the B*2709 mutants. The CTL
line PMC6 tested only in the B*2705 context, showed lack of
reactivity towards pLMP2 on both mutants. No CTL line, either
pVIPR- or pLMP2- specific, was able to lyse untransfected HeLa
cells incubated with the relevant peptide (data not shown).
These results demonstrate that the Arg62, located in the A-
pocket of HLA-B27 binding groove, could play an important role
as TCR docking residue.
Arg62 is crucial for TCR recognition also when the
peptide possesses a p1 residue different from Arg
The effect of Arg62 substitutions in the B27 molecules was also
investigated with a peptide not having Arg at position 1. In this
Figura 4. CTL recognition of pVIPR displayed by R62K and R62A B*2705/09 mutants and by wt subtypes. 4 h standard
51chromium-
release assay showing the reactivity pattern of pVIPR responsive CTLs raised in B*2705 positive patients with AS (EP and BAR) against HeLa cells
transfected with B*2705 and 09 molecules or expressing the indicated mutant forms. These cells used as targets have been pulsed ON with pVIPR
(70 mM) or cultured in medium alone. Effector/target ratio was 15:1. Bars represent the mean percentage of lysis 6 SD of three independent
experiments.
doi:10.1371/journal.pone.0032865.g004
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stabilizes peptides with pArg1 is different. To address this issue, we
tested the recognition of NPflu by a specific CTL line (SER62)
derived from a B*2705 positive individual. As expected, the
B*2709 molecules were not able to present the peptide because of
the Arg at the C-terminus (Fig. 6). In the B*2705 context, the non-
conservative substitution R62A abrogated the peptide recognition
while R62K mutant showed a 35% reduction of lytic activity
compared to the wt molecules. This result obtained with a B27
epitope having Ser instead of Arg at P1, suggests a general
relevance of Arg62 for TCR recognition of B27/peptide
complexes that is only partially influenced by the amino acid
specificities at P1 residue.
Discussion
Subtype- and peptide-dependent structural and dynamical
features of the HLA:peptide complexes dictate the conditions for
T-cell recognition and are likely to be involved in the differential
association of some HLA-B27 subtypes with AS. To investigate
this matter, a combination of theoretical and experimental
procedures was employed.
We focused on the interactions established by the Arg62 inside
the A pocket that anchors the peptide N-terminus. This is a
residue of the a1-helix, highly conserved in the alleles of the HLA-
B locus (.95%) whose orientation could be strongly influenced by
the P1 residue of the specific ligand [51,52]. In all resolved B27
crystal structures, this arginine is oriented towards the binding
groove, frequently forming water-mediated salt bridges to Glu163
on the opposed a2-helix, thereby clamping the peptide in the
binding groove. In contrast, available MHC:peptide:TCR struc-
tures suggest an engagement of Arg62 in TCR binding implying
an exposed Arg62 conformation. Examples are given by the
allogeneic H-2K
b MHC class I molecule bound to an octapeptide
and the KB5-C20 TCR (PDB ID: 1KJ2 2.71 A ˚) [33]; the HLA-
B*0801 in association with a nonamer from EBNA3A of EBV
bound to the LC13 TCR (PDB ID: 1MI5 2.50 A ˚) (Fig. 1B) [34]
and the HLA-B*3501 in complex with the endecapeptide EPLP
bound to ELS4 TCR (PDB ID: 2NX5 2.70 A ˚) [35]. In the HLA-
B*3501 and HLA-B*0801 structures, four key aminoacids Arg62,
Gln65, Ala150, Gln155 are engaged by specific residues of the
respective bound TCRs. All these residues are shared by B*2705
and B*2709 subtypes. The same residues, with the exception of
Gln155 replaced by Arg155, are involved in the contacts between
H-2K
b subtype and the KB5-C20 T-Cell receptor.
Accordingly, Webb and colleagues [53] predicted that the
Arg62 in the H2-Kb e H2-Kbm8 would contact the CDR1a of the
anti-HSV T lymphocytes and, serving as ‘‘electrostatic guide for
TCR docking’’, would be pivotal for T-cell selection depending on
its dynamics and positioning.
The tight Arg62-pArg1-Trp167 stacking interaction has been
invoked as a possible explanation for the relative high frequency,
in the B27 repertoire, of peptides with dibasic N-terminal motif
pArg1-pArg2 [30], that, however, have an intrinsic resistance to
cytosolic degradation. To this regard, it has been shown that
mutations of Glu163 alone or both Glu163 and Trp167 had a
limited effect on the B*2705 molecules for usage of peptides with
basic P1 residues, thus indicating that the increased cytosolic
stability is responsible for such a preferential binding [54].
However, B*2705 mutants substituted at Arg62 residue have
Figura 5. CTL reactivity against pLMP2 bound to R62K and R62A B*2705/09 mutants and wt molecules. pLMP2-driven CTL lines derived
from a B*2705 positive patients with AS (PIC) and two B*2709 positive individual (DE and PMC) have been tested in a 4 h standard
51chromium-
release assay using HeLa transfectants expressing wt or mutants of B*2705 and B*2709 subtypes as target cells after ON treatment with pLMP2
(70 mM) or in absence of peptide. Effector/target ratio was 15:1. Mean percentage of lysis 6 SD of three separate experiments is shown here.
doi:10.1371/journal.pone.0032865.g005
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repertoire.
Here, we have investigated the structure and dynamics of the
Arg62-Glu163 peptide clamp pair in MD simulations of the HLA-
B*2705/09 subtypes bound to peptides with arginine (pVIPR,
pLMP2, TIS) and serine (NPflu) at the N-terminal peptide
position, under physiological conditions. In our computational
setting, all MD simulations of B*2705 and B*2709 subtypes bound
to peptides with pArg1 (pVIPR, pLMP2 and TIS) revealed a very
large conformational flexibility of the Arg62 side chain. Notably,
during the 400 ns simulation, the contact between Arg62 and
Glu163 present in the respective crystal structures was lost
(examples are shown in Figure 2A) and the side chain of Arg62
adopts a flexible exposed conformation, similar to that displayed in
the MHC-peptide/TCR complexes reported above (see also
Fig. 1B). This conformational change with the exposed Arg62
was stable in the majority of simulated systems except for B*2705
bound to pVIPR both in the canonical and non-canonical
conformations. Here, the Arg62-Glu163 bond is intermediately
re-established. The Arg62 reorientation is accompanied by a
partial rearrangement of the A pocket. The Arg62 re-orientation
was favourable when Arg1 could interact with Glu163 or when
other positively charged residues such as pArg3 in pLMP2 or
pLys3 in pVIPR could form a transient or stable salt bridge with
Glu163. In contrast, with a polar residue present at P1 as Ser in
NPflu, the system showed a marked different energetic profile with
a tightened Arg62-Glu163 clamp across the peptide, although not
present in the crystal [45]. Thus, the peptide sequence dictates the
conformation of TCR-accessible heavy chain amino acids. Several
MHC:peptide:TCR crystal structures reported in the literature as
well as our molecular dynamics simulations suggested a key role
for Arg62. For a deeper comprehension of its relevance to the
B*2705 and B*2709 molecular stability and, more importantly, to
the antigen presentation to TCR, we generated HeLa cells stably
expressing R62A and R62K B27 mutant forms. Both conservative
and non-conservative substitutions did not significantly change the
cell surface expression level of B27 mutants as inferred by
comparison with wt B*2705 and B*2709 alleles (Fig. 3). This was
observed by flow cytometry analysis with ME1 [49], a mAb
recognizing the properly folded B27 molecules or with HC10 [50]
that reacts against the free heavy chains. Therefore, a change in
the expression level and/or molecular stability of the mutants did
not bias T-cell data.
A comparison of T-cell results for pVIPR and pLMP2 presented
by the wt molecules and by the R62A and R62K B27 mutants
suggests a relevance of R62 for TCR interaction. For all but one
CTL line (EP1), the mutations in Arg62 led to a significant
decrease or even total abrogation of lytic activity with respect to
pVIPR presentation by wt B27 molecules. Interestingly, the EP1
CTL line displayed a full activation by R62K and R62A B*2705
mutants but not by the same mutants in the B*2709 context. We
do not expect that mutations of Arg62 lead to a different
distribution of pVIPR conformations observed in crystal structures
in complex with B*2705 and thereby to a modified T-cell
response. The crystal structures of both conformations show a
similar interaction pattern in this region of the binding groove.
For pLMP2 presentation in the disease-associated B*2705
context, both mutants are less effective than wt in activating the
CTL lytic activity with the non-conservative R62A mutant
working slightly worse than the conservative R62K mutant. This
order is reversed in the case of peptide presentation by the non-
disease associated B*2709 (Fig. 5) suggesting different TCR
binding modes to B*2709 as compared to B*2705. DE5 CTL
provides a striking example: it failed to react against pLMP2 when
presented by R62A B*2705 mutant while it was activated by the
same mutant in the B*2709 context. All together, these data
strongly suggest that R62 mutations in the A pocket could be
differently buffered in respect to TCR recognition by the His-Asp
polymorphism at 116 in the F pocket. Also T cell recognition of
NPflu, the only peptide analysed here having Ser at P1, appeared
to be influenced by mutations at R62 in the B*2705 context while,
as already mentioned, it is not presented by the B*2709 subtype.
As for the cases of B*2705 presenting pLMP2 or pVIPR, CTL
activity required a positively charged residue at position 62 (R or
K). This result is consistent with previous T-cell recognition data
showing that the side chain of pSer1 was not directly involved
in interactions with the TCR but rather the region around
P1 represents a docking site for the TCR. Accordingly, the
replacement of pSer1 by amino acids with bulky side chains (R, K
or Y) induced a marked reduction of T-cell recognition due to the
steric interference with TCR binding [45,55].
This combined experimental and theoretical study would
suggest a differential contribution of Arg62 to the TCR
recognition of B*2705/09:peptide complexes. MD simulations of
the wt B27:peptide systems revealed the meta-stability of the
Arg62-Glu163 peptide clamp frequently observed in crystal
Figure 6. Recognition of Npflu associated to R62K and R62A
B*2705/09 mutants and wt molecules. Cytotoxic activity of a
specific CTL obtained from a B*2705 positive subject (SER) against HeLa
cells transfected with wt and B*2705 and B*2709 mutants and
incubated with NPflu peptide (70 mM) or in medium alone and used
as targets. Effector/target ratio was 15:1. Bars represent the mean
percentage of lysis 6 SD of three independent experiments.
doi:10.1371/journal.pone.0032865.g006
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exposed, TCR oriented side-chain conformation. Functional
experiments showed that the positive charge of Arg62 is preferred
for the TCR recognition of disease-associated B*2705 complexes.
Differently, a small amino acid such as Ala is favourable over Lys
in the non-disease-associated B*2709 subtype. In conclusion, this
study gives a strong indication for a B27 subtype-dependent
functional role of Arg 62 in the antigen recognition by TCR.
Materials and Methods
Ethics Statement
This study has been approved by the Ethics Committee of the
University of Cagliari where blood samples of patients with AS
and healthy controls have been collected (365/09/CE). All
participants involved in this study gave their written informed
consent.
MD simulations
The starting structures of the HLA-B*2709 and HLA-B*2705
proteins presenting the peptides studied here were taken from the
Protein Data Bank (PDB entries: 1UXW: B*2709 with pLMP2 at
1.71 A ˚ [29], 61UXS: B*2705 with pLMP2 at 1.55 A ˚ [29], 1OF2:
B*2709 with pVIPR at 2.20 A ˚ [28], 1OGT: B*2705 with pVIPR
in canonical (VIPR A) and non-canonical (VIPR B) conformation
at 1.47 A ˚ [28], 1W0W: B*2709 with TIS at 2.11 A ˚ [32], 1W0V:
B*2705 with TIS at 2.27 A ˚ [32]. Additionally the HLA-B*2705-
peptide complex with the immunodominant viral peptide from
influenza nucleoprotein (NPflu) NP383–391 was also investigated
(PDB ID: 2BST) at 2.10 A ˚ [45].
Protonation states of the titratable groups present in the
investigated proteins [56] were chosen according to results of
pKa calculations performed on the studied systems using the
WHATIF package [57].
The GROMACS software package [58] (version 4.0.4) with the
OPLS-AA/L all-atom force field [59] was used to carry out the
MD simulations. The proteins were solvated in a dodecahedron
box, imposing a minimum distance between the protein and the
box of 1.4 nm. Almost 27,000 TIP4 water molecules were added
to the different systems [60]. Na
+ and Cl
2 ions were added to the
systems in order to reproduce the physiological ionic concentration
(0.15 M). An excess of Na
+ was added to compensate for the net
negative charge of the MHC complexes. The long-range
electrostatic interactions (distances .1.0 nm) were computed by
the Particle Mesh Ewald (PME) method [61]. The short-range
electrostatic interactions were treated explicitly with a non-bonded
pairlist cut off of 1.0 nm. The bond lengths of the hydrogen atoms
were constrained by applying the Lincs algorithm thus permitting
the use of a time step of 2 fs for numerical integration of the
equations of motion [62]. The temperature was kept constant by
coupling the system to an external thermal bath (310 K) with a
coupling time constant tT=0.1 ps [63]. The systems were weakly
coupled to a pressure bath (1 Bar) [63] with a coupling time
constant tp=1.0 ps. 200 steps of energy minimization (steepest
descent algorithm), followed by 100 ps of MD simulation with
harmonic position restraints (force constant 1000 kJ mol
21 nm
22)
on the heavy atoms of the protein preceded the production runs.
All MD simulations were run for 400 ns (2610
8 integration steps),
adding up to a total simulated time of 3.2 ms.
Synthetic peptides
The following peptides have been used in this study: pVIPR
(RRKWRRWHL, 400–408) from human vasoactive intestinal
peptide type 1 receptor [26]; pLMP2 (RRRWRRLTV, 236–244)
[16] from Epstein-Barr virus latent membrane protein 2; NPflu
(SRYWAIRTR, 383–391) [15,45] from influenza A virus
nucleoprotein; TIS (RRLPIFSRL, 325–333) [24] from TIS11B,
member of epidermal growth factor early response genes. Peptides
were purchased from PRIMM GmbH (Dubendorf, Zuerich, CH),
dissolved in 100% DMSO and their concentration estimated by
BCA test according to the manufacturer’s protocol (Pierce,
Thermo scientific, IL, USA).
B27 mutants and cDNA cloning
cDNAs encoding for B*2705 and B*2709 had been cloned in
pCEP4 mammalian expression vector (Invitrogen, Carlsbad, CA,
USA) as reported previously [23]. The mutated constructs were
generated by PCR-based cassette mutagenesis of the B*2705 and
B*2709 wt cDNAs by using the following primers: (forward) 59-
GCCCGGTACCGGACTCAGAATCTCCTCAG-39 and (re-
verse) 59-CAATACTCCGGACCCTCCTGCTCTATCC-39 that
amplify part of HLA-B27 cDNA upstream to the codon encoding
for R62. This 240 bp fragment that included part of 59-UTR of
HLA-B27, introduced a KpnI site (underlined) at 59-end and a
Kpn2I site (underlined) at 39-end. A second PCR was performed
to introduce the specific mutation R62A and R62K using as
primers: forward for R62A substitution 59-GAGGGTCCGGAG-
TAT TGGGACGCGGAGACAC-39 (in bold the codon intro-
ducing the mutation) and forward for R62K substitution 59-G-
AGGGTCCGGAGTATTGGGACAAGGAGACA-39 (in bold the
codon introducing the mutation) and reverse, 59- CCGCAA-
GCTTCTGGGGAGGAAACACAGGTCAGCGGAAC-39 (the
same for all mutants). These primers amplified a fragment of
900 bp and introduced a Kpn2I site at 59-end (underlined) and a
HindIII site (underlined) at 39-end. The PCRs were conducted in a
standard buffer with 2.5 mM MgSO4, 10 pmol of each primers,
0,2 mM of dNTP mix, 1,25 U of Pfu Taq Polymerase (Fermentas,
Thermo scientific, IL, USA) and H2O to a final volume of 50 ml.
After a first step at 94uC (30 s), annealing at 62uC (30 s), and
extension at 72uC (30 s) for 5 cycles, other 27 cycles were run at
94uC (30 s), 66uC (30 s), 72uC (30 s), before a final extension at
72uC (7 min) in a GeneAmp PCR system 9700 Thermal cycler
(Applied Biosystems, Carlsbad, CA, USA). The PCR products were
sequentially digested with KpnI (Fermentas, Thermo scientific, IL,
USA) and Kpn2I (Fermentas, Thermoscientific, IL,USA) asfor the
fragment of 240 bp and with Kpn2I and HindIII (Fermentas,
Thermo scientific, IL, USA) as for the fragment of 900 bp and then
purified from agarose gel by using GFX
TM PCR DNA and Gel
Band Purification Kit (GE Healthcare Europe GmbH, MI, Italy).
Afterwards, the 240 bp and the 900 bp fragments of the respective
B27 subtypes were mixed at ratio of 5:5:1 with pCEP4 vector cut
with KpnI and HindIII and gel purified using the same kit as above.
The ligations were conducted overnight at 16uC with T4 DNA
ligase(NewEngland Biolabs, Beverly,MA). XL1-Blue Escherichia coli
electrocompetent cells (Stratagene; Agilent Technologies, Italy)
were transformed by the products of ligations and several colonies
for each subtypes were screened by B27-specific PCR and the
positive ones checked by automated DNA sequencing.
Transfection of HeLa cells
HeLa cells (ATCC number CCL2
TM; www.atcc.com/) were
transfected with pCEP4 constructs containing cDNAs for wt
B*2705 and B*2709 and R62A and R62K mutants using
Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. After transfection,
cells were diluted in DMEM supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin and 100 mg/mL streptomycin at 1610
6 cells/mL.
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transfection with 200 mg/mL hygromycin B (PAA, Pasching,
Austria). After two weeks of culture, cells were diluted at one cell/
well in 96-well flat-bottom microplates and clones, stably
expressing B27 molecules, were selected and used to perform
subsequent experiments.
mAbs and immunofluorescence
For immunofluorescence experiments, cells were stained with
ME1 (a conformational dependent IgG1mAb, recognizing HLA-
B27, -B7, -B42, -B67, -B73 and Bw22) [49] and HC10 (a IgG2a
mAb, reacting with a determinant on b2-microglobulin free heavy
chains of HLA-B, -C and some HLA-A alleles) [50] and then by
F(ab’)2 of rabbit anti-mouse FITC (Jackson ImmunoResearch
Europe Ltd., Suffolk, UK). Isotype matched mouse Igs were used
as negative controls to define background staining. Flow cytometry
analysis was made immediately after staining, without fixation, by
using a FACSCalibur (BD Biosciences). For each sample, 10.000
events were acquired using forward/side light scatter character-
istics and analyzed using Cell Quest software (Becton Dickinson).
Cell lines
Autologous B lymphoblastoid cell lines (B-LCLs) from B27
positive subjects were generated by in vitro immortalization of B
cells using the standard type 1 Epstein-Barr virus isolate B95.8
[23] and cultured in RPMI (Lonza, Basel Switzerland) supple-
mented with 10% fetal calf serum, 2 mM L-glutamine, 100 units/
ml penicillin, 100 mg/ml streptomycin. wt and transfected HeLa
cells, described above, were cultured in DMEM (Lonza, Basel
Switzerland) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin.
HeLa transfectants were cultured in presence of 200 mg/ml
hygromycin B (PAA, Pasching, Austria) to maintain the expression
of B27 molecules.
Generation of antigen-specific CTL lines
Peripheral blood mononuclear cells from B*2705 positive
patients with AS and healthy donors, either B*2705 or B*2709
positive, were isolated by density gradient centrifugation with
Lymphoprep and depleted of the CD4+ T cells by Dynabeads M-
450 CD4+ (Dynal ASA, Oslo, Norway). Cell cultures were seeded
at 1610
4 cells/well in 96-well flat-bottom microplates and
stimulated by autologous B-LCLs at 0.5:1 antigen-presenting
cells/responder ratio. The antigen-presenting cells had been
pulsed overnight with pVIPR (70 mM), pLMP2 (50 mM) or NPflu
(50 mM) peptides before being c-irradiated (200 Gy). CTL lines
were grown in RPMI 1640 medium supplemented with 10% heat-
inactivated pooled human serum, 2 mM L-glutamine, 100 U/mL
penicillin and 100 mg/mL streptomycin. 20 units/ml human rIL-2
(Roche Applied Science) was added to each well after 3 days. CTL
lines were then re-stimulated on day 10–12. One week later, the
specificity of CTL lines was tested by a standard
51Cr release assay
using as targets peptide-pulsed autologous B-LCL and T2B*2705
transfectants [64]. Phenotypic analysis of peptide-specific CTL
lines was performed by immunostaining using the following
monoclonal antibodies: OKT3, OKT4, and OKT8 (Orthodiag-
nostics, Stanford, CA). CTL lines were maintained in culture by
weekly stimulation with c-irradiated autologous B-LCL in
complete RPMI medium (see above) and human rIL-2 (20–
100 units/ml), and were used for functional assays 8–10 days after
stimulation. The study has been approved by the Institutional
Review Board of the University of Cagliari were blood samples
have been collected.
51Cr-Release Assay
Specific reactivity of CTL lines towards pVIPR, pLMP2 and
NPflu was tested by a standard 4-h
51Cr-release assay. Target cells
(HeLa transfectants either expressing wt B*2705 and B*2709
molecules or R62A and R62K mutated forms) were incubated
overnight with the different peptides at indicated concentrations or
cultured in medium alone. One day later, target cells were labeled
with sodium
51chromate, washed and plated (3610
3 target cells/
well) with effector T cells at 15:1 effector/target ratio, in absence
of free peptide.
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